INT J LAB HEMATOL:中国欠发达地区范可尼贫血快速诊断方法评价

2019-01-31 MedSci MedSci原创

范可尼贫血(Fanconi, FA)是一种先天性骨髓衰竭综合征,与获得性再生障碍性贫血(acquired aplastic, AAA)相似,特征为严重的骨髓细胞不足和全血细胞减少。然而,需要FA或AAA患者进行准确的诊断,因为这两种综合征在治疗和预后上都存在显著差异。FA是由于DNA修复特异性的FA通路基因发生基因突变而导致的,这些基因的突变导致FA细胞基因组不稳定。基于这一特点,染色体畸变(CA

范可尼贫血(Fanconi, FA)是一种先天性骨髓衰竭综合征,与获得性再生障碍性贫血(acquired aplastic, AAA)相似,特征为严重的骨髓细胞不足和全血细胞减少。然而,需要FAAAA患者进行准确的诊断,因为这两种综合征在治疗和预后上都存在显著差异。FA是由于DNA修复特异性的FA通路基因发生基因突变而导致的,这些基因的突变导致FA细胞基因组不稳定。基于这一特点,染色体畸变(CA)AAA被用作FA辅助诊断的金标准,但CA诊断需要更多的技术要求,后续的统计分析也需要很长的时间。本研究中,研究人员采用两个基因组不稳定性检查工具:胞质分裂块微核(CBMN)和单细胞凝胶电泳(SCGE)来区分FA病人和AAA病人。

结果表明,所有三个基因组不稳定性检查工具在FA患者中存在显著差异结果(与AAA病人和对照组比较)。然而,在比较时间成本、仪器成本和技术成本时,CBMN是三种基因组不稳定检测工具中区分FA患者和AAA患者最经济有效的方法。因此,在经济技术受限的地区,CBMN可作为鉴别FAAAA患者的替代方法。

原始出处:

Kaihua Ji Yangyang Kong Yang Liu, Evaluation on the genetic instability detecting methods for rapid diagnose of Fanconi anemia used in the undeveloped areas of China

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709882, encodeId=999d1e09882ae, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Thu Aug 15 15:29:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723568, encodeId=f89a1e23568de, content=<a href='/topic/show?id=dde98e1711d' target=_blank style='color:#2F92EE;'>#范可尼贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87171, encryptionId=dde98e1711d, topicName=范可尼贫血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7533484263, createdName=chenlianhui, createdTime=Thu Jun 06 10:29:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317470, encodeId=dd52131e47087, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444493, encodeId=e801144449334, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709882, encodeId=999d1e09882ae, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Thu Aug 15 15:29:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723568, encodeId=f89a1e23568de, content=<a href='/topic/show?id=dde98e1711d' target=_blank style='color:#2F92EE;'>#范可尼贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87171, encryptionId=dde98e1711d, topicName=范可尼贫血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7533484263, createdName=chenlianhui, createdTime=Thu Jun 06 10:29:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317470, encodeId=dd52131e47087, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444493, encodeId=e801144449334, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709882, encodeId=999d1e09882ae, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Thu Aug 15 15:29:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723568, encodeId=f89a1e23568de, content=<a href='/topic/show?id=dde98e1711d' target=_blank style='color:#2F92EE;'>#范可尼贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87171, encryptionId=dde98e1711d, topicName=范可尼贫血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7533484263, createdName=chenlianhui, createdTime=Thu Jun 06 10:29:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317470, encodeId=dd52131e47087, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444493, encodeId=e801144449334, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709882, encodeId=999d1e09882ae, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Thu Aug 15 15:29:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723568, encodeId=f89a1e23568de, content=<a href='/topic/show?id=dde98e1711d' target=_blank style='color:#2F92EE;'>#范可尼贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87171, encryptionId=dde98e1711d, topicName=范可尼贫血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7533484263, createdName=chenlianhui, createdTime=Thu Jun 06 10:29:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317470, encodeId=dd52131e47087, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444493, encodeId=e801144449334, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:29:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 huagfeg

相关资讯

Blood:来自范可尼贫血患者的经基因校正过的CD34+细胞的移植情况及增值优势。

范可尼贫血(Fanconi anemia)是一种罕见的常染色体隐形遗传性血液系统疾病,属于先天性再生障碍性贫血。该类病人除了典型再障表现外,还伴有多发性的先天畸形(皮肤棕色色素沉着、骨骼畸形、性发育不全等)。中心点:通过对CD34+细胞的优化采集和短期转化,首次证明可对范可尼贫血再生细胞进行表型校正。优化范可尼贫血患者的CD34+细胞的体外基因疗法,稳固表型校正后的重回输细胞的增殖优势。摘要:既往

Cell:范可尼贫血基因也在自噬和免疫中发挥功能

2016年5月3日/生物谷BIOON/--在一项新的研究中,来自美国德州大学西南医学中心(UTMC)、印第安纳大学医学院和三家欧洲科研机构的研究人员鉴定出范可尼贫血(Fanconi anemia, FA)途径中的基因的重要新功能,这一发现可能对开发用于治疗这种疾病和一些癌症的新疗法产生影响。相关研究结果于2016年4月28日在线发表在Cell期刊上,论文标题为“Fanconi Anemia

范可尼贫血启发癌症治疗新思路

       范可尼贫血(Fanconi anemia)是一种隐性遗传疾病,每35万个婴儿中就有一人患病。该病让细胞不能修复DNA损伤。因为修复能力的缺乏,范可尼贫血症患者是很多癌症的高危人群,尤其是白血病以及头部和颈部癌症。        更糟糕的是,这种疾病使得病人不能使用一大类癌症药物,这类药物(